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Abstract
Background:
Measles, mumps, rubella, and varicella were common diseases
in the United States prior to the introduction of their respective
vaccines. There are still regions in the world where these diseases
are highly prevalent. Even after dramatic reductions in the
prevalence of measles, mumps, rubella and varicella in the United
States, there continue to be outbreaks of these diseases, stressing
the need for ongoing immunization and pre-traveling counseling.
Most prior studies of seroprevalence for these viral diseases are
often based on national surveillance data. It is therefore important
to get a clearer understanding on the local level of immunity so
that more focused recommendations can be made for our patient
population.
Leftover, non-duplicate outpatient serum samples obtained in
Lehigh Valley Pennsylvania were tested for IgG antibodies using
commercially available enzyme immunoassays to mumps, measles,
rubella, and varicella. Samples were collected sequentially, and deidentified. Five birth cohorts were created and 460 samples were
collected as follows: <1957 (52), 1957-1966 (109), 1967-1976
(117), 1977-1988 (121), and 1989-1995 (61).

Results:

Overall seroprevalence (excluding equivocal results) for measles,
mumps, rubella, and varicella were (%): 85.8, 82.8, 96.6, and 97.4.
There was a significant association between seroprevalence and
birth cohort for measles (p=0.010) and mumps (p=0.037) only.
Pairwise comparisons of the cohorts found that for measles there
was a significant difference between the <1957 versus 1967-1976
(p=0.005) cohort and the <1957 versus 1989-1995 (p=0.001)
cohort. Additionally, the overall seroprevalence for our study sample
was significantly different than national seroprevalence results for
rubella, mumps, and measles.

Conclusion:

Our study on local seroprevalence showed dramatically lower
immunity rates to measles and mumps than prior national
seroprevalence studies have shown. The rates in many of the later
birth year cohorts were significantly lower than rates reported
necessary to sustain herd immunity. The results of this study show
the tremendous value in determining seroprevalence on a local
basis. We will use these results to alter our approach to assessing
travelers and others in our clinics based on their birth year.

Mean+SD

Range

Less than 1957

72.6±9.7

58-96

1957 to 1966

52.0±2.8

47-57

1967 to 1976

41.8±2.7

37-47

1977 to 1988

31.2±3.5

25-37

1989 to 1995

21.5±2.0

18-25

Male N (%)

US
% Immune

P-value

Rubella1

96.1

89.4

<0.001

Measles3

87.2

93

<0.001

Mumps4

82.4

90

<0.001

Disease

Study Benefits:
•	Results of this study will be helpful to guide the approach used when assessing a traveler’s vaccination needs.
•	Data collected will help identify age groups in our region at risk of acquiring vaccine-preventable diseases.
Study Limitations:
•	Our study may be subject to sampling bias due to utilization of a non-probability sampling method.
•	Local immunity rates may have been underestimated as we did not evaluate for cellular immunity through vaccination
records.

Figure 1.
Percentage of Birth Cohort Immune to Each Disease
(Excluding Equivocal)

Table 2: Gender by Birth Cohort
Birth Cohort

LVHN
% Immune

100

Female N (%)

95

Total N (%)

Less than 1957

27(51.9)

25(48.1)

52(100)

85

1957 to 1966

51(46.8)

58(53.2)

109(100)

80

1967 to 1976

59(50.4)

58(49.6)

117(100)

1977 to 1988

58(47.9)

63(52.1)

121(100)

1989 to 1995

28(45.9)

33(54.1)

61(100)

100

98.1
96.1

97.2
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Discussion

Table 3: LVHN Overall Seroprevalence by Disease Compared to
National Seroprevalence (Excluding 1989 - 1955 Cohort)

Table 1: Age by Birth Cohort
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•	Our study, performed in the Lehigh Valley, PA on the local seroprevalence for four vaccine preventable diseases (MMRV)
showed dramatically lower immunity rates to measles and mumps than previously reported on several national
seroprevalence surveys.
•	The immunity rates for many of the later birth cohorts were significantly lower than the rates necessary to sustain herd
immunity.
•	The results of this study show the critical value in determining the local seroprevalence. In the presence of ongoing global
outbreaks, the importance of fostering routine childhood vaccinations and promoting pre travel advice is paramount.
•	Future studies should be encouraged to document regional and local seroprevalences to vaccine preventable diseases
throughout the US; to properly advise pre-traveling immunization.

Future Directions

Birth Cohort

•	There was a statistically significant association between birth cohort and immune status for
both mumps (p=0.037) and measles (p=0.010).
•	For measles, the immunity rates of birth cohorts 1967-1976 and 1989-1995 were
significantly lower when compared to birth cohort <1957 (82.4% vs 98.1%, p=0.005 and
77.2% vs 98.1%, p=0.001, respectively).
•	More males than females showed humoral immunity to measles in the 1989-1995 cohort,
92.6% of males vs 63.3% of females (p=0.009).
•	Our local seroprevalence to measles, mumps, and rubella was significantly different than
that reported for the national seroprevalence (p<0.001).
•	No statistically significant association between gender and immunity was found for mumps,
rubella or varicella.
•	No statistically significant association between birth cohort and immunity status was found
for rubella or varicella.
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•	Creating a seroprevalence study using a probability sampling method and a larger sample size.
•	Expansion of demographic data collection (country of birth, race/ethnicity, family income, education level and religious/ethical
beliefs) will help to minimize potential confounders of immunity status.
•	To include vaccination records of the sample population to evaluate for cellular immunity.
•	Further asses the low immunity rates in youngest birth cohorts.
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